Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Fuji
Farmers Insurance
Harvard Business School
Dow
US Department of Justice
Cantor Fitzgerald
McKinsey
Fish and Richardson

Generated: April 21, 2018

DrugPatentWatch Database Preview

PHOSLO Drug Profile

« Back to Dashboard

Which patents cover Phoslo, and what generic alternatives are available?

Phoslo is a drug marketed by Fresenius Medcl and is included in two NDAs. There are two patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in PHOSLO is calcium acetate. There are two hundred and seventy-five drug master file entries for this compound. Thirty-three suppliers are listed for this compound. Additional details are available on the calcium acetate profile page.
Drug patent expirations by year for PHOSLO
Pharmacology for PHOSLO
Synonyms for PHOSLO
62-54-4
AC1L1LU9
AC1LANU5
Acetate of lime
acetic acid calcium salt
Acetic acid, calcium salt
Acetic acid, calcium salt (2:1)
AI3-02903
AKOS015904560
AN-23726
API0024654
Brown acetate
Brown Acetate of Lime
Ca(OAc)2
Calac
Calcium acetate
Calcium Acetate (Fragrance Grade)
Calcium acetate (USP)
Calcium acetate [USAN:JAN]
Calcium acetate [USP:JAN]
Calcium Acetate 23% 10M
Calcium acetate hydrate, Puratronic
calcium acetate salt
Calcium Acetate, FCC
CALCIUM ACETATEULTRA PURE
Calcium di(acetate)
Calcium diacetate
calcium diacetate, CAc - acetic acid, calcium salt
calcium ethanoate
calcium(2+) bis(acetate ion)
calcium(II) acetate
CCRIS 4921
CHEBI:3310
CHEMBL1200800
D00931
D0F1GS
DB00258
DTXSID0020234
E263
EC 200-540-9
EINECS 200-540-9
Eliphos
FEMA No. 2228
FT-0623376
GE2473
Gray acetate
Gray Acetate of Lime
Grey acetate
HSDB 928
I14-16503
IN017428
J-519530
Lime acetate
Lime pyrolignite
LS-2337
Niacet calcium acetate tech
OR033975
OR205936
Phoslo (TN)
Phoslo Gelcaps
Phoslyra
Procalamine
Pyrolignite of lime
RP22176
Sanopan
SC-18378
SCHEMBL23872
Sorbo-calcian
Sorbo-calcion
Teltozan
UNII-Y882YXF34X
Vinegar salts
VSGNNIFQASZAOI-UHFFFAOYSA-L
Y882YXF34X

US Patents and Regulatory Information for PHOSLO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Fresenius Medcl PHOSLO calcium acetate CAPSULE;ORAL 021160-001 Apr 2, 2001 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Fresenius Medcl PHOSLO GELCAPS calcium acetate CAPSULE;ORAL 021160-003 Apr 2, 2001 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Fresenius Medcl PHOSLO calcium acetate CAPSULE;ORAL 021160-002 Apr 2, 2001 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Fresenius Medcl PHOSLO calcium acetate TABLET;ORAL 019976-001 Dec 10, 1990 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for PHOSLO

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Fresenius Medcl PHOSLO calcium acetate TABLET;ORAL 019976-001 Dec 10, 1990 ➤ Try a Free Trial ➤ Try a Free Trial
Fresenius Medcl PHOSLO calcium acetate CAPSULE;ORAL 021160-001 Apr 2, 2001 ➤ Try a Free Trial ➤ Try a Free Trial
Fresenius Medcl PHOSLO calcium acetate CAPSULE;ORAL 021160-002 Apr 2, 2001 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for PHOSLO
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Capsules EQ 169 mg calcium ➤ Subscribe 2005-05-31

Non-Orange Book US Patents for PHOSLO

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,875,445 Encapsulated calcium acetate caplet and a method for inhibiting gastrointestinal phosphorous absorption ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
McKinsey
Healthtrust
Medtronic
Baxter
Teva
Federal Trade Commission
US Department of Justice
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.